United KingdomFinance and insurance2020 – ongoingMedicash
SkinVision screening for policyholders
Medicash reported 1,000 clinically validated skin-cancer detections among policyholders using SkinVision
Problem
Medicash sought to make skin-health assessments more accessible to policyholders and support earlier investigation of suspicious lesions.
Approach
Medicash introduced SkinVision to policyholders in 2020. Members uploaded skin photographs for risk assessment, with follow-up clinical validation by specialist dermatologists. Medicash identified SkinVision as an AI skin-cancer detection service in its financial condition report.
Results
Takeaway
The reported detections covered Medicash policyholders specifically. The total did not establish the service's sensitivity or how many cancers would otherwise have been missed.
Categories
- Size
- Small business
- Industry
- Finance and insurance
- Business function
- Customer service
- Innovation type
- Product and service innovation
- AI technology
- Computer vision
- Adoption
- Vendor solution
- Evidence
- Company's own claim
Sources
Source summaries
Medicash reported its 1,000th clinically validated skin-cancer detection among policyholders using SkinVision since 2020. It described photographic risk assessments and follow-up validation by dermatologists.
Medicash identified SkinVision as an AI skin-cancer detection service within its digital benefits. It said corporate policyholders received the service at no extra charge.
Full details are in the original sources.